As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Core Scientific, Inc. The largest reported stake is Two Seas Capital LP's, at 6.3%. One filing is on record since August 8, 2025 (Schedule 13D, August 8, 2025).
Sell to companies like Core Scientific, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Core Scientific, Inc. has 1 Schedule 13D or 13G filing on record since 2025-08-08. 1 holder's latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Stated intent
Intent stated in Item 4 Two Seas Capital LP
The Reporting Persons intend to solicit proxies against the Issuer's proposal to adopt the Merger Agreement at the Special Meeting and also intend to file a proxy statement in connection with the Special Meeting, if and when it is scheduled.From Item 4 of the SCHEDULE 13D filed 2025-08-08
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Two Seas Capital LP | 6.3% | 19,122,842 | SCHEDULE 13D, 2025-08-08 | 2025-08-07 |
Holding shares or following this stake? See who's behind Core Scientific, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Core Scientific, Inc. and the records around it.
Companies that share a holder
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
Watch Core Scientific, Inc.
Get an email when Core Scientific, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Core Scientific, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Core Scientific, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Core Scientific, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Two Seas Capital LP
The Reporting Persons acquired the securities reported herein for investment purposes in the ordinary course of business. The Reporting Persons acquired such securities because they believed that such securities, when purchased, represented an attractive investment opportunity. On July 7, 2025, the Issuer, CoreWeave, Inc., a Delaware corporation ("CoreWeave"), and Miami Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of CoreWeave ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides, upon the terms and subject to the conditions set forth therein, for a merger between Merger Sub and the Issuer, with the Issuer surviving as a wholly owned subsidiary of CoreWeave. On August 7, 2025, TSC issued a press release containing an open letter to the Issuer's shareholders (the "August 7 Letter") expressing its intent to vote against adoption of the Merger Agreement and the reasons therefor at the upcoming special meeting of stockholders of the Issuer (the "Special Meeting"), a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The Reporting Persons intend to solicit proxies against the Issuer's proposal to adopt the Merger Agreement at the Special Meeting and also intend to file a proxy statement in connection with the Special Meeting, if and when it is scheduled. The foregoing description of the August 7 Letter does not purport to be complete and is …The first part of Item 4 of the SCHEDULE 13D filed 2025-08-08; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-08 | Two Seas Capital LP intent stated | 6.3% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Core Scientific, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.